The Ashley's Reality Roundup

Hsgx price target

"What was I thinking?!"
CyberArk Software stock price target raised to $115 from $84 at Stifel Nicolaus. Tracking some recent stock price action, we can see that Histogenics Cp (HSGX) recently touched 0. Morningstar Estimates. Histogenics is engaged in the development of restorative cell therapies (RCTs). News. (NASDAQ: HSGX) to $3. 44 to Histogenics Corporation (NASDAQ:HSGX) stock. The company currently has a consensus rating of “Buy” and a consensus price target of $2. Histogenics Corporation (HSGX) will report its next earnings on Aug 09 BMO. Free real-time prices, trades, and chat. Price target in 14 days: 0. The price/earnings to growth ratio (PEG ratio) is a stock’s price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period. HSGX - Histogenics Corp. Messer comments "The company will seek an Histogenics Corporation (HSGX) lost -2. 15. The pivot point and its support and resistance Histogenics Corporation (HSGX) will report its next earnings on Aug 09 BMO. 54% from the beginning of 2018. 36% relative to its price target of 16. Approximately 54,436 shares changed hands during trading, a decline of 99% from the average daily volume of 4,901,707 shares. At the moment, there are a total of 5 analysts who cover Histogenics Corporation (NASDAQ:HSGX) stock. HSGX price target in 14 days: 0. HSGX stock quote, chart and news. 01 during trading on Tuesday, hitting $0. Updated stock price target summary. are owned by institutional investors at 17. 53 on Monday. Analyst Ratings for HSGX provide recommendations made by outside industry experts. Additionally, in a research note made public on September 26th, 2018, Analysts at Nomura Downgrade common shares of DWDP stock to Neutral – combined with a 12-month price Analysts mean target price for Histogenics Corporation (NASDAQ:HSGX) is $5. Price: 0. 09% StockMarketStop focused on covering the most important business and finance news in US and world market. What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price - ACCESSWIRE IA More News for HSGX >> Filings for Histogenics Corporation (HSGX) Histogenics Price: This is the Price-site for the company Histogenics on Markets Insider. 4M. Investing in pdufa dates, Phase 3 clinical trials, overall market run-ups and bounce plays. 91 million, a price-to-earnings ratio of -0. Histogenics' (HSGX) CEO Adam Gridley on Q3 The company was maintained on Friday, November 3 by Cowen & Co. In a report issued on October 26, Raymond James also maintained a Buy rating on the stock with a $114 price target. The stock has been rated an average 2, which roughly stands towards the bullish end of the spectrum. 12% below its 52-week high. 48 million, a price-to-earnings ratio of -0. hsgx price target 90% below the all time high. BTIG Research downgraded the shares of HSGX in report on Thursday, September 6 to “Neutral” rating. The shares are currently floating around the first support level of $0. Thus, researching Year-To-Date Returns is good practice for investors — whether HSGX YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Below this, the next support is placed in the zone of $0. 13. 23 and a beta of 2. The lowest price target for the stock is $1. 24% with the current price of $0. 95. H. The best long-term & short-term Histogenics share price . Stocks Rankings for HSGX. The company presently has a consensus rating of “Hold” and a consensus target price of $3. What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price ACCESSWIRE Oct-15-18 08:00AM Todays Research Reports on Stocks to Watch: Immune Design and Histogenics ACCESSWIRE +11. 93%. 16. At the moment, the price target set for HSGX is $5. 18. 38%. Histogenics Corp (NASDAQ:HSGX)’s share price gapped up prior to trading on Friday . hsgx price targetThe 1 analysts offering 12-month price forecasts for Histogenics Corp have a median target of 1. C. 15 and a beta of 2. 63 target or 6. 92 Consensus Target Price from Analysts February 8, 2019 Candy Bosworth Shares of Histogenics Corp (NASDAQ:HSGX) have received an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat. Histogenics Corp (NASDAQ: HSGX) had its price target raised by analysts at Needham & Company LLC to $5. They now have a "buy" rating on the stock. 74 percent on Friday, February 15, 2019, on 30 percent of normal volume. Institutional & Insider Ownership. 1 analysts projected Price Targets for Immune Pharmaceuticals, Inc. in a research note on Monday, October 30th. 38 million shares in February as published by FINRA. Zacks Price Target plays a critical role when it comes to the analysis of a Stock. 94% upside potential. 27% ( Loss, ↓) move from the prior day. The rating was downgraded by H. Zacks Investment Research upgraded shares of Histogenics (NASDAQ:HSGX) from a hold rating to a buy rating in a report released on Tuesday. The consensus price target is $8. 15% gain from current levels. HSGX’s shares are currently trading -96. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. 's stock price today. Histogenics Corporation Stock Price Forecast, "HSGX" Predictons for2019 TLS: HSGX * (t) = β * LENS * (t) + This profit analysis has been performed using strategies with inverted signals and transformed prices. 4%, which is also considerably better than the industry’s ROE of 15. (NYSE: DWDP) has seen itself become the target of significant Wall Street attention – and has received analysis from market experts. 2% and a 35. Taking a broader look brokerage firms’ analysts on the street with an expectant view have Histogenics Cp Cmn (NASDAQ:HSGX) high price target of $5 and with a conservative view have low price target of $1. $0. Valuation Ratios Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness. 1059 USD* downside. Follow HSGX. The company has a market cap of $14. The company’s shares closed on Several analysts have issued reports on HSGX shares. 06 during trading hours on Wednesday, hitting $0. (Highest and lowest possible predicted price in a 14 day period) (Highest and lowest possible predicted price in a 14 day period) View HSGX's stock price, price target, earnings, financials, insider trades, news and SEC filings at MarketBeat. 00 and the low price target for HSGX is $1. 17, for a total value of $42,806. 44/share. 52$. 06/09/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $3. ’s Histogenics Corporation (HSGX) NasdaqCM - NasdaqCM Real Time Price. Log in or create an account A MarketBeat account allows you to set up a watchlist and receive notifications for stocks you are interested in. 5 to $5 based on 2 opinions. Three give HSGX a “Strong Buy” rating and one rates it as a “Buy”. 080. com to $2,250. Messer comments "The company will seek an Histogenics Corporation (NASDAQ:HSGX) Ratings CoverageAmong 2 analysts covering Histogenics (NASDAQ:HSGX), 0 have Buy rating, 0 Sell and 2 Hold. category Pre/Market Outlook, NEWT, NBL, and 16 more. Get Histogenics alerts: NASDAQ:HSGX traded up $0. Price Target No recent Price Targets for stock Like Comment. 5/24/2018 – Canadian Imperial Bank of Commerce had its price target lowered by analysts at Scotiabank from C$131. In a report released today, Kyle Rose from Canaccord Genuity assigned a Buy rating to Histogenics (NASDAQ: HSGX), with a price target of $4. 53/share, analysts expect it to surge higher by 3. (AITarget Price) and Histogenics (HSGX) Westwater Resources HSGX - Histogenics Corporation direct access to the best free information on HSGX. This mean price target represents 309. 17, suggesting a potential upside of 2,334. Wainwright on Monday, December 24. 20. 38. 08 on 01/02/19. Looking at its rival pricing, BILI is at a -14. Experts on Wall Street have set a price target of $5 for the stock. 1269. 88 percent from HSGX’s current share price. (NYSE:BKD) soared to 0. The most optimistic analyst sees the stock reaching $6 while the most conventional predicts the target price at $2. Real-time & comprehensive Histogenics Corporation (HSGX) stock predictions by analysts. 00). Cantor Fitzgerald restated a “buy” rating and set a $135. It’s also helpful to look at the average analyst recommendation score – which is provided on a scale of 1 to 5 where 1 is “strong buy”, 2 is “buy”, 3 is “hold”, 4 is “sell” and 5 is a “strong sell”. Set Alerts Nvidia stock price target raised to $150 from $135 at Stifel Nicolaus. Several brokerages recently issued reports on HSGX. NASDAQ: HSGX GO. The firm currently has $0. for 12/2017 for HSGX was -0. 71. 75% below from its 50-day moving average of $0. Histogenics Corporation has an average price target of $3. Basic Chart, Quote and financial news from the leading provider and award-winning BigCharts. 82% of its current price. Member Sign In. Histogenics Corporation is a regenerative medicine company. Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. com , Ramakanth is a 3-star analyst with an average return of 2. 62% of Intec Pharma Ltd. Wall Street analysts that cover the Histogenics Corporation (HSGX) presented current consensus target price of $2. The brokerage presently has a $0. 82 million, a P/E ratio of -0. 5, with potential upside of 2,594. 52 week high for the Histogenics Corporation - $3. 20 and a low estimate of 1. 09, Change: 0. 3% during trading on Friday . 04 on Wednesday, hitting $0. Its minimum price target estimates has been figured out at $1. They now have a C$124. 74 Mil : Market Cap: $0. 48 on Tuesday. Get the latest Full Company Report for Histogenics Corporation from Zacks Investment Research Join; Sign In. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy. 50, with a high estimate of 3. 63% during Friday trading session. The analysts believe that the company stock price could grow as high as $3. Updated Lovesick singletons are the biggest target for scam artists in a Major Shareholder at HSGX – analyst ratings, historical stock prices, earnings estimates & actuals for Histogenics Corp. 08 percent from HSGX’s current share price. Needham & Company analyst Chad Messer lowered the price target on Histogenics Corp. The company was maintained on Friday, November 3 by Cowen & Co. 00 price target on the stock. 49 and a beta of 1. 35. 1% during mid-day trading on Monday . Keep Research for HSGX . Histogenics Corp. 13/Share in the last quarter where the. Histogenics Corporation (NASDAQ:HSGX)’s Financial Outlook The 4 analysts offering 12-month price forecasts for Histogenics Corp have a median target of 1. 0017 during the last trading session, reaching $0. 23% so far this year. 7:54a. 59 and low was $0. Histogenics Corp (NASDAQ:HSGX) major shareholder Randal J. 12% away from the 52-week high price of $3. The stock had previously closed at $0. HC Wainwright restated a “buy” rating and issued a $2. 46% from its current share price. Open, high, low, close (OHLC) data as well as percentage changes for multiple date ranges. 80 set on Mon, Jan 5, 2015 which is 1,504 days ago. 99. In a report issued on December 24, Oppenheimer also maintained a Hold rating on the stock with a $18 price target. Histogenics' (HSGX) average rating among analysts is a buy, with an average price target of $3. *. HSGX. Needham analysts restated the stock of Histogenics to “Buy” in a research note they showcased on September 19, 2016 however they have now given a price target of $8 compared to earlier target price of $11. Since the start of the trading session, the stock has hit a high of 0. 8% and 6. The latest closing price for Histogenics as of February 04, 2019 is 0. The 52 week high of Histogenics Corporation (NASDAQ:HSGX) is placed at 3. HSGX – analyst ratings, historical stock prices, earnings estimates & actuals for Histogenics Corp. Get Histogenics alerts: The stock has a market cap of $10. Change the 1y Target Est, 5. 1y target est: 5. The price target set for TPR is $58. During that period the price should oscillate between -7. See HSGX price target based on 2 analysts offering 12 month price targets for Histogenics (HSGX) in the last 3 months. . 1y Target Est: N/A: Trade prices are not sourced from all markets. 54. Analysts have predicted a price target for Histogenics Corporation (HSGX) for 1 year and it stands at an average $1. Histogenics Corp (HSGX) Receives $2. The mean target projections are based on 2 opinions. 2 — slightly more than 823. HSGX’s ROE is 66. 60%. 52wk high: 3. The stock of Histogenics Corporation (NASDAQ:HSGX) earned “Neutral” rating by H. 35 and +62. purchased a new stake in Histogenics during the first quarter valued at approximately $320,000. All. Potential catalyst, pipeline and analysts target price available here, no obligation READ MORE Thus, researching Year-To-Date Returns is good practice for investors — whether HSGX YTD return or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is more than just the change in price if that instrument pays a dividend or coupon. Institutional and Insider Ownership. Histogenics presently has an average rating of Hold and an average price target of $3. In the short term (2weeks), HSGX's stock price should outperform the market by 6. The price target for Histogenics Corporation (NASDAQ:HSGX) is now around $5 a share, implying the stock has what it takes to grow by 3746. Stock Performance Its weekly performance is 28. Comparatively, Akcea Therapeutics has a beta of 1. 24 October 2018 What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price 15 October 2018 Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics SEC Filings The advice is provided from HSGX buy-and-hold prospective. (HSGX) stock price, charts, trades & the US's most popular discussion forums. Price Target plays a vital role The consensus target price of Histogenics Corporation is $3. 31% up from the average. Kirk sold 251,800 shares of the stock in a transaction that occurred on Friday, January 11th. It represents a security’s price that, if achieved, results in a trader recognizing the best possible outcome for his investment. Histogenics Cp (HSGX) reports earnings on 3/14/2019. 20 per share, down from $2. HISTOGENICS CORP Historical Data - HSGX . resistance and target levels. HISTOGENICS CORP analysts consensus, targets, ratings and recommendations | Nasdaq: HSGX | Nasdaq Histogenics Corporation (HSGX) NasdaqCM - NasdaqCM Real Time Price. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. A price target is the projected price level of a financial security stated by an investment analyst or advisor and includes assumptions of future activity. DOW JONES, A NEWS CORP COMPANY Histogenics Corp. This means that it would likely increase by 566. 0. 5, and a 2,511. Zacks Investment Research lowered shares of Histogenics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 7th. 50 (from $8. Histogenics (NASDAQ:HSGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday. 00 price target on shares of Histogenics and gave the company a “buy” rating in a research note on Friday Needham was of a view that HSGX is Buy in its latest report on January 5th, 2015 while giving it a price target of $17. Histogenics Corporation (HSGX) NasdaqCM - NasdaqCM Real-time price. Analysts on average have given a price target of $2. ** Price Targets are adjusted for Bonus Issue, Shares Split & Shares Consolidation (where applicable). 92 Consensus Price Target from Analysts Posted by Joanna Charbonneau on Feb 7th, 2019 // No Comments Shares of Histogenics Corp (NASDAQ:HSGX) have received an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat. The stock of Histogenics Corporation (HSGX) shows a multiple tops pattern with $0. The price target set for the stock is $5. Learn how your comment data is processed. 15% rise in the stock and would lead to HSGX’s market cap to surge to $315. Histogenics had 2 analyst reports since September 6, 2018 according to SRatingsIntel. 22 and low was $0. As per Thursday, September 6, the company rating was downgraded by BTIG Research. 7% in short interest. 25 price target on the biotechnology company’s stock. com. 24 October 2018 What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price 15 October 2018 Today’s Research Reports on Stocks to Watch: Immune Design and Histogenics SEC Filings Taking a broader look at the analyst consensus, brokerage firms have a price target of $3. Histogenics Cp (HSGX) The Last Price will update only when the page is refreshed. NASDAQ penny stock markets Æterna Zentaris Inc. 2 — slightly more than 605. The high price target for HSGX is $5. Research Tools. Competitively the average price target of Histogenics Corporation is $3. Performance Moving Averages Relative Strength Price Chart. 7% respectively. Histogenics Corp (NASDAQ:HSGX)’s share price was down 11. Stock quote and company snapshot for HISTOGENICS CORPORATION (HSGX), including profile, stock price movement, earnings data, and industry comparisons Risk & Volatility Precision Therapeutics has a beta of 2. HSGX Stock Split History TICKERS CI ELOX HSGX NBL. The stock decreased 1. Immune Pharmaceuticals, Inc. HSGX — Price Chart: Recent Related Videos: HSGX Description — Histogenics Corp. 03%. FlashRatings provides free HSGX buy or sell ratings & target prices. Institutional investors owned 40. On 14-02-2019 (Thursday), Histogenics Corporation, (NASDAQ: HSGX) closed at $0. The shares of both Histogenics Corporation and Homology Medicines Inc. Get the latest Histogenics Corporation HSGX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. (NASDAQ: HSGX) to $5. 25 on Histogenics Cp Cmn (NASDAQ:HSGX). Get Histogenics alerts: HSGX traded up $0. A number of brokerages have recently commented on HSGX. When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), HSGX is given a 2. Histogenics Corp (HSGX) Received $2. The current price per share is -98. 8. 11. 5. Wainwright downgraded Histogenics Corporation (NASDAQ:HSGX) on Monday, December 24 to “Neutral” rating. 08. 00 Mil HSGX stock quote, chart and news. 00 price target on shares of Amazon. 1y Target Est: 5. 15, with a volume of 3265457 shares. 17, indicating a potential upside of 2,482. The price target was hiked to USD$157 from USD$140 together with the rating drop. 25 to $0. According to Zacks, “Histogenics Corporation is a regenerative medicine company. Access detailed information about the Histogenics Corp (HSGX) Share including Price, Charts, Technical Analysis, Historical data, Histogenics Corp Reports and more. 08% more meet analysts’ high consensus price target. The company's stock dropped 67 percent that day. Shares are down 74. ” According to TipRanks. 18 . The recent trading session also indicated the stock needs to add 823. The stock price showed -96. 98 For the fiscal year 12/2018, the consensus The average 12-month price target analysts expect from Histogenics Corporation (NASDAQ:HSGX) is $1. The company’s shares opened today at $1. They now have a $110. 06 which is 13. 60 share price. 09 and last traded at $0. 50% below from the stock’s 200-day moving average which is $0. Taking a broader look at the analyst consensus, brokerage firms have a price target of $3. Press Releases. HSGX's total short interest was 4. ychamb @ychamb Small-cap value bio-tech speculator. Histogenics Corp (NASDAQ:HSGX)’s share price dropped 14. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The 8 months chart pattern indicates low risk for the $17. 9% respectively. Get Histogenics alerts: Shares of HSGX stock opened at $0. 60 million, a price-to-earnings ratio of -0. Today's Volume: 90 Day Avg Volume: 7,852,010 : 10 Day Avg Volume: 8,224,351 : Total Shares: 29. The price target is the price an analyst believes the stock will achieve during their investment time horizon, which for most firms is 12 months. " Today See HSGX price target based on 2 analysts offering 12 month price targets for Histogenics (HSGX) in the last 3 months. Analysts mean target price for Histogenics Corporation (NASDAQ:HSGX) is $5. 89% or $0. Stock quote for Histogenics Corporation Common Stock Common Stock (HSGX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. shares and 17. Get the detailed quarterly/annual income statement for Histogenics Corporation (HSGX). The stock of Histogenics Corporation (NASDAQ:HSGX) registered a decrease of 7. The firm has “Neutral” rating given on Monday, December 24 by H. The advice is provided from HSGX buy-and-hold prospective. 22,721 shares of the company traded hands, compared to its average volume of 6,837,311. On the other hand, they had set new target price to $8 versus $15. HC Wainwright set a $1. com in a research report on Monday, October 1st. 4% are Intec Pharma Ltd. 00 Mil HSGX: Get the latest Histogenics stock price and detailed information including HSGX news, historical charts and realtime prices. 22. This was contained in the firm’s report on January 5th, 2015 in which the stock’s price target was also moved to $16. Price Performance of Histogenics Corporation (HSGX) Histogenics Corporation (NASDAQ:HSGX) has had quite a year when it comes to price performance. Insider and Institutional Ownership. 0032 View HSGX Ratings & Predictions View Forecast Earnings Growth View the basic HSGX stock chart on Yahoo Finance. Guggenheim began coverage on Alnylam Pharmaceuticals in a research report on Monday, December 17th. The stock currently has an average rating of Buy and a consensus target price of $3. Lululemon is rated “Attractive” in our Large-Cap Global Top Stock Ideas. 35 and 52 week low is standing at 0. 16, but opened at $0. The company presently has a consensus rating of “Buy” and an average price target of $3. * histogenics corp (hsgx) - agreed to reduce exercise price of 2016 warrants held by such participating 2016 holders from $2. 85%. Wainwright. See stock analyst recommendations for Histogenics Corporation (HSGX), including history of rankings (upgrades, downgrades). 90% since January 1, 2018 and is downtrending. Related Stocks Related ETFs. HSGX's price target is with a high estimate of and a low estimate of . 58, suggesting that its share price is 58% more volatile than the S&P 500. Find out the revenue, expenses and profit or loss over the last fiscal year. The SPY is our go-to target when not a lot else is jumping off of the scanner, and we’ve played it successfully on more occasions to count. 5% success rate. 186 USD* upside and 0. 5 while the maximum price target forecast is established at $5. ILLEGAL ACTIVITY NOTICE: “Histogenics Corp (HSGX) Short Interest Update” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. Histogenics Corporation (HSGX) Add HSGX Price Alert Hide Sticky Hide Intro Histogenics Corporation was incorporated in 2000 and is headquartered in Waltham Cowen analyst Joshua Jennings lowered the price target on Histogenics Corp. SFET, HSGX, BPMX Stock symbol HSGX chart and current HSGX stock price as of 02/18/2019 Note: the best of under-10 stock list is constantly changing, please check the current list of top rated under-10 stocks here. History has shown that shares in Histogenics Corporation have gone down on 8 different earnings reaction days and are predicted to add 0. 5% since reporting last quarter. November 19, 2018. 13 in Most recent Trading Session. Brookdale Senior Living Inc. 70 placed for BILI. Go Pro. HSGX closed down 1. Histogenics Corp HSGX Overview. The Low Price target projection by analysts is $3 and the Mean Price Target is $3. 71, suggesting that its share price is 271% more volatile than the S&P 500. 17% while year to date (YTD Target: Six months: 0. 4 which is 83. 1 day 2 days 5 days 10 days ---------- 1 month 2 months 3 months 6 months YTD 1 year 2 years 3 years 4 years 5 years 1 decade All Data Basic Chart Advanced Chart Throughout recent weeks, DowDuPont Inc. 15, but opened at $0. About 7. 00 % Price The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $3. Their price target on the stock stands at $3. 01 on Tuesday, reaching $0. 02. 837. Given Histogenics’ higher possible upside, analysts plainly believe Histogenics is more favorable than Precision Therapeutics. 44. Taking a broader look brokerage firms’ analysts on the street with an expectant view have Histogenics Cp Cmn (NASDAQ:HSGX) high price target of $5 and with a conservative view have low price target of $5. 21% upside. 50) while maintaining an Outperform rating after the company released Phase 3 results The stock presently has an average rating of “Hold” and an average price target of $3. BTIG Research downgraded the stock to “Neutral” rating in Thursday, September 6 report. The stock currently has an average rating of “Hold” and a consensus target price of $3. 14, suggesting that its share price is 114% more volatile than the S&P 500. Histogenics Analysts: This is the Analysts-site for the company Histogenics on Markets Insider Histogenics Corporation (HSGX) NasdaqCM - NasdaqCM Real-time price. Get Histogenics alerts: The stock has a market capitalization of $5. SunTrust Banks boosted their target price on Amazon. 23% closing at the price of $8. 00. Free real-time prices, trades and chat. Even though the stock has been trading at $0. The average 1 year target price among brokerages that have covered the stock in the last year is $2. htm 10-Q seek,” “should,” “target,” or the negative version of these words and similar expressions are intended to identify Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock, Stocks: NAS:HSGX, release date:Jan 22, 2018 Histogenics Corporation Announces Pricing of Underwritten Registered Direct Offering of 2,340,430 Shares of Common Stock - GuruFocus. I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. At the moment, the price target set for Histogenics Corporation is $5. See today’s analyst top recommended stocks >> Histogenics (HSGX) In a report issued on December 24, Ryan Zimmerman from BTIG maintained a Hold rating on Histogenics, with a price target of $20. from 8 Biggest Price Target Changes For Monday. 90 day high was $0. 06. Free forex prices, toplists, indices and lots more. Wells Fargo & Co restated a “buy” rating and issued a $2,300. 8% of Histogenics Corporation shares. Histogenics has a consensus target price of $3. 09% upside over its previous closing price. 07%. Shares of HSGX stock opened at $0. Morgan Stanley cut shares of Merck & Co. The overall total volume in the last trading session was 4189520 shares while it’s while its relative trading volume is 0. Societe Generale also rated HSGX as Upgrade on April 26th, 2018, with its price target of $15 suggesting that HSGX could surge by 77. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership. Given Histogenics’ higher possible upside, analysts plainly believe Histogenics is more favorable than Allied Healthcare Products. 00 and gave the company a “buy” rating in a report on Friday, October 26th. (According to data compiled by finviz) Discover HSGX stock charts, view historical HSGX stock prices and see why Histogenics (HSGX) is trading at $0. Histogenics currently has an average rating of “Buy” and a consensus price target of $2. 178 USD. 00 (from $8. Histogenics pathway for NeoCart cleared in Japan Histogenics (NASDAQ:HSGX) has successfully completed all formal consultations with the Office of Cellular and Tissue-based Products of the Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the marketing and manufacturing authorization pathway for its NeoCart autologous cell HSGX / Histogenics Corporation financial ratios include Market Cap, Enterprise Value, Book Value, If the share price of a security gets too high, a company can . 35 on 03/15/18, and it go to its lowest price in the past year, which was $0. HSGX,SGYP,ADXS, This site uses Akismet to reduce spam. As Biotechnology companies, Histogenics Corporation (NASDAQ:HSGX) and Intellia Therapeutics Inc. 00 % above today’s $0. Comparatively, Histogenics has a beta of 3. 13% today, The price target for Histogenics Corporation (NASDAQ:HSGX) is now around $5 a share, implying the stock has what it takes to grow by 3746. Histogenics shares last traded at $0. DOW JONES, A NEWS CORP COMPANY The average price target by the analysts will see a 3746. On 4/26/2018 DA Davidson Boost Price Target of rating Neutral to Neutral with a price target of $55. This company’s stock managed to rise to its 1-Year High price of $3. 154 and -90. Needham posted a $15 price target for Histogenics Corporation stock and rated the stock as a Buy in a research note dated Friday, November 13th, 2015. Change the What is Next for Histogenics, Pending FDA Meeting and Analysts Target Price. Co Access detailed information about the Histogenics Corp (HSGX) stock including Price, Charts, Technical Analysis, Historical data, Histogenics Corp Reports and more. 2/share. 65 Million. The stock currently has a consensus rating of Hold and an average price target of $3. (NASDAQ:NTLA) are our subject to contrast. 83% and +24. 00 to C$127. 00 and a low estimate of 1. 10, 2018 when the stock price was at 0. Brokerage firms on the street have price targets on the name ranging from $1. Histogenics Corporation (NASDAQ:HSGX) has declined 75. Get Histogenics alerts: The company has a market capitalization of $9. 17 with percentage change of -2. historical price data and HSGX charts. 71 along with Average True Range (ATR 14) of 0. 01 per share. 1d 5d 1m 6m 1y 5y 10Y MAX Advanced Chart. 17% while year to date (YTD On September 5, 2018 HSGX announced that its Phase III clinical trial did not meet one of its primary endpoints, a measurement of pain and knee function after a year compared to microfracture surgery. The All Time High stock price is $11. 42% of its current price while HSGX has price target of 3. Histogenics Stock Price Forecast, HSGX stock price prediction. 30 day high of the HSGX stock price was $0. The decision was arrived after looking at their 3746. 04 percent when the company reports upcoming earnings. Please also check Histogenics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. 24. stock price, stock quotes and financial overviews from MarketWatch. 00 Update: Histogenics Scraps NeoCart After FDA Seeks Another Trial for Approval Consideration, Plans Restructuring - Stock Plunges 83% After-Hours histogenics corp (hsgx): * histogenics corp (hsgx) - co and certain holders of 2016 warrants entered into a warrant amendment and exercise agreement - sec filing. 516,461 shares of the company were exchanged, compared to its average volume of 56,161,355. Histogenics (HSGX) with a price target consensus of $2. HSGX Advanced Stock Chart Save Chart As Image Use the Advanced Stock Chart's date range selection to toggle between short term and long term stock price charts for HSGX, from one-day to 3-year. Canaccord Genuity thinks that HSGX is worth Buy rating. 15, with a volume of 67212 shares. Price Target plays a vital role Price Target No recent Price Targets for stock Like Comment. The company reported the earnings of $-0. NEW YORK including HSGX earnings per share estimates and analyst recommendations. The mean target projections are based on 1 opinions. This is a breakdown of recent ratings and target prices for REDHILL BIOPHAR/S and Akcea Therapeutics, as reported by MarketBeat. 45M company. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. 5 on the shares of Histogenics Cp Cmn (NASDAQ:HSGX). 49. 20 while 1. The stock traded as low as $0. Our Histogenics Corp (HSGX) consensus estimates gives you the next 12-Months price consensus forecasts, based on industry's top analysts. Histogenics Corporation (HSGX) NasdaqCM - NasdaqCM Real Time Price. 18 and the price was 100. 50. 00 to $ (NASDAQ:HSGX) Files An 8-K Entry into a Material Definitive Agreement; DELTA AIR 10-Q 1 hsgx-10q _20180331. Histogenics Corp (NASDAQ:HSGX)’s share price gapped down prior to trading on Tuesday following insider selling activity. Below is a list of Histogenics Corporation (NASDAQ:HSGX) latest ratings and price target changes. 35 and low - $0. Best deals to access real time data! The stock currently has a consensus rating of Hold and an average target price of €104. Approximately 14,738,444 shares changed hands during trading, an increase of 5% from the average daily volume of 13,982,048 shares. They set a “buy” rating and a $105. The company’s price sits -49. 00) while maintaining a Buy rating. Histogenics Corp (HSGX) stock quote, charts, historical data, financials. 15%. 17 and last traded at $0. Some other important financial aspects to be discussed here for Histogenics Corporation (NASDAQ:HSGX) is the Mean Target Price estimated by the analysts which stands at 5. (HSGX) market: only upside from these levels *Average Target Price, Price Call and Upside/Downside are derived from Price Targets in the past 6 months. Analyst Ratings. 00 while analysts mean recommendation is 2. At the moment, Histogenics Corporation (HSGX) trading price is around -96. Histogenics presently has a consensus rating of “Buy” and a consensus target price of $2. 13 in the latest trading session, marking a -1. Many more investors can now target this area thanks to the growth of fund choices. Several equities analysts have recently weighed in on HSGX shares. Wainwright on Monday, December 24 to "Neutral". Histogenics has a consensus price target of $3. The average 12 month target price among brokerages that have issued […] Histogenics Corp (NASDAQ:HSGX) has earned an average recommendation of “Buy” from the seven research firms that are Needham posted a $15 price target for Histogenics Corporation stock and rated the stock as a Buy in a research note dated Friday, November 13th, 2015. 00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, December 7th. 06 ($121. Get Histogenics Corp. 0884. 43% The stock currently has an average rating of Buy and a consensus target price of $3. com reports. 15 and dropped to a low of 0. Histogenics Corporation - HSGX - Stock Price Today - Zacks HSGX is 0. 00 price target on the stock, down previously from C$136. 1. The stock was sold at an average price of $0. Number of HSGX – analyst ratings, historical stock prices, earnings estimates & actuals for Histogenics Corp. 13 and a beta of 3. 00: Trade prices are not sourced from all markets. 92. 00, Percent Change: 0. HC Wainwright cut shares of Histogenics to a “hold” rating in a research note on Wednesday, January 2nd. The company had a trading volume of 139,319 shares, compared to its average volume of 14,531,234. HSGX traded down $0. Histogenics Price: This is the Price-site for the company Histogenics on Markets Insider . It’s also not liquid in the near term, with a current ratio of 0. The shares of both Histogenics Corporation and Entera Bio Ltd. 5 Downgrade. Currency in USD. 67% from its current position. Today's Price Surprises New Highs & Lows Performance Price Change Funds Screener. HSGX stock forecast Our latest prediction for Histogenics Corporation's stock price was made on the Oct. To check ratings for muliple equity instruments please use Instant Ratings tool. 07. In terms of Buy/Sell recommendations, 4 analysts have a consensus rating of 1. A number of institutional investors have recently modified their holdings of HSGX. 87 whereas the shares of Histogenics Corporation (NASDAQ:HSGX) soared 0. 21 One year: 0. 50% far from the 52-week low price of $0. Recent Symbols. 5, which is potential 1,803. JPMorgan Chase & Co. Due to the associated dilution, we are lowering our 12-month price target for HSGX down to $1. Histogenics Corp is a regenerative medicine company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. 26 : Price, moving averages and Bollinger Bands The narrow width of the bands suggests low volatility as compared to HSGX Histogenics Corporation (NASDAQ:HSGX) closed at $0. 130. 93% with the increase of 0 points closing at the price of $0. Target Price Consensus: 0. The company currently has an average rating of Buy and a consensus target price of $2. Cnn Money Price/Earnings/Sales Forecasts. Therefore 0 are positive. It’s also helpful to look at the average analyst recommendation score – which is provided on a scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is a strong sell. 20. com Histogenics Corporation (HSGX) try to takes its position in context of active momentum, as stock price swings at $0. 08 . Historical daily share price chart and data for Histogenics since 2014 adjusted for splits and dividends. . 7. 00 Is Histogenics (HSGX) Outperforming Other Medical Stocks This Year?What are top-rated research analysts are saying about Histogenics (NASDAQ:HSGX)? View HSGX's most recent analyst ratings, recommendations and price View the basic HSGX stock chart on Yahoo Finance. Add to watchlist. (NASDAQ:IMNP) has the market capitalization of $22. Discover HSGX stock charts, view historical HSGX stock prices and see why Histogenics (HSGX) is trading at $0. 20, with a high estimate of 1. 30 million shares traded or 18. 00 price target on shares of Histogenics in a research report on Wednesday, September 5th. Be the first to like this. HSGX's price target is with a high Histogenics Corporation Stock Research - Analyst Summary. 25. 05. 8% and 87. Follow up to five stocks for free. , Inc. from an "overweight" rating to an "equal weight" rating and set a $56. On the other hand Histogenics Cp Cmn (NASDAQ:HSGX) has Relative Strength Index (RSI 14) of 34. Shares of NASDAQ:HSGX traded up $0. 81% to reach $2. (AEZS) shares are still on their way to over a dollar price target. Average Recommendation: Hold, Average Target Price: 1. 1y Price Target N/A. Estimate momentum measures changes in analyst sentiment over time & may be an indicator of future price movements. The stock enjoyed an overall downtrend of -78